IP Library Granted Patent US 8,431,367
Granted Patent B2
US 8,431,367 · App. 13/161,074 · Granted Apr 30, 2013

Detection of nucleic acids and proteins

Inventor: Anthony P. Shuber (Mendon, MA)
Assignee: Predictive Biosciences Corporation
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 8,431,367
App. No.
13/161,074
Granted
Apr 30, 2013
Kind
B2
Abstract

The invention generally relates to methods for detecting a target nucleic acid and a target protein in a single assay.

Claims (35)

1. A method of detecting multiple analytes in a sample, the method comprising the steps of:

obtaining a sample comprising at least one target nucleic acid and at least one target protein;

introducing an aptamer that binds to the target protein in the sample;

removing unbound aptamer; and

conducting a single assay, wherein the assay detects both the target nucleic acid and the target protein, the assay comprising: performing a sequencing reaction on the target nucleic acid and the aptamer, wherein sequencing comprises: hybridizing a primer to each of the nucleic acid and the aptamer to form each of a nucleic acid/primer duplex and an aptamer/primer duplex; contacting each of the duplexes with a polymerase enzyme in the presence of at least one detectably labeled nucleotide under conditions that permit the polymerase to add nucleotides to the primers in a template-dependent manner; detecting a signal from the incorporated labeled nucleotide; and sequentially repeating the contacting and detecting steps at least once, wherein sequential detection of incorporated labeled nucleotide determines the sequence of each of the nucleic acid and the aptamer thereby detecting the nucleic acid and the aptamer in the sample.

2. The method according to claim 1 , further comprising quantifying the target nucleic acid.

3. The method according to claim 1 , further comprising quantifying the target protein.

4. The method according to claim 1 , further comprising quantifying the target nucleic acid and the target protein.

5. The method according to claim 1 , wherein prior to sequencing, the nucleic acid and the aptamer are attached to a substrate.

6. The method according to claim 5 , wherein the nucleic acid and the aptamer are directly attached to the substrate.

7. The method according to claim 5 , wherein the nucleic acid and the aptamer are indirectly attached to the substrate.

8. The method according to claim 1 , wherein prior to sequencing, the method further comprises amplifying the nucleic acid.

9. The method according to claim 1 , wherein sequencing is sequencing by synthesis.

10. The method according to claim 9 , wherein the sequencing by synthesis is single molecule sequencing by synthesis.

11. The method according to claim 1 , wherein the detectably labeled nucleotide is an optically labeled nucleotide.

12. The method according to claim 11 , wherein the optically labeled nucleotide is a fluorescently labeled nucleotides.

13. The method according to claim 1 , wherein the target nucleic acid is associated with a disease.

14. The method according to claim 13 , wherein the disease is cancer.

15. The method according to claim 13 , wherein the target nucleic acid is selected from the group consisting of: FGFR3, K-ras, K-ras2, APC, DCC, TP53, PRC1, NUSAPI1, CAPZ, PFKP, EVER1, FLT1, ESPL1, AKAP2, CDC45L, RAMP, SYNGR2, NDRG1, ZNF533, and hypermethylated nucleic acid.

16. The method according to claim 1 , wherein the target protein is associated with a disease.

17. The method according to claim 16 , wherein the disease is cancer.

18. The method according to claim 17 , wherein the target protein is selected from the group consisting of: MMP-2, MMP-9, MMP9/NGAL complex, MMP/TIMP complex, MMP/TIMP1 complex, ADAMTS-7, ADAM-12, thymosin 15, thymosin 16, profilin, prohibitin, ubiquitin, tropomyosin, Cyr61, cystatin B, and chaperonin 10.

19. A method for diagnosing a disease, the method comprising:

obtaining a sample comprising at least one target nucleic acid and at least one target protein, each of which is suspected of being associated with a disease;

introducing an aptamer that binds to the target protein in the sample;

removing unbound aptamer;

conducting a single assay, wherein the assay detects both the target nucleic acid and the target protein, the assay comprising: performing a sequencing reaction on the target nucleic acid and the aptamer; wherein sequencing comprises: hybridizing a primer to each of the nucleic acid and the aptamer to form each of a nucleic acid/primer duplex and an aptamer/primer duplex; contacting each of the duplexes with a polymerase enzyme in the presence of at least one detectably labeled nucleotide under conditions that permit the polymerase to add nucleotides to the primers in a template-dependent manner; detecting a signal from the incorporated labeled nucleotide; and sequentially repeating the contacting and detecting steps at least once, wherein sequential detection of incorporated labeled nucleotide determines the sequence of each of the nucleic acid and the aptamer; and

diagnosing the disease based on results of the assay.

20. A method for diagnosing a cancer, the method comprising:

obtaining a sample comprising at least one target nucleic acid and at least one target protein, each of which is suspected of being associated with a cancer;

introducing an aptamer that binds to the target protein in the sample;

removing unbound aptamer;

conducting a single assay, wherein the assay detects both the target nucleic acid and the target protein, the assay comprising: performing a sequencing reaction on the target nucleic acid and the aptamer; wherein sequencing comprises: hybridizing a primer to each of the nucleic acid and the aptamer to form each of a nucleic acid/primer duplex and an aptamer/primer duplex; contacting each of the duplexes with a polymerase enzyme in the presence of at least one detectably labeled nucleotide under conditions that permit the polymerase to add nucleotides to the primers in a template-dependent manner; detecting a signal from the incorporated labeled nucleotide; and sequentially repeating the contacting and detecting steps at least once, wherein sequential detection of incorporated labeled nucleotide determines the sequence of each of the nucleic acid and the aptamer; and

diagnosing the cancer based on results of the assay.

21. The method according to claim 20 , wherein the cancer is bladder or colorectal cancer.

Assignments (2)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Apr 18, 2014
From: PREDICTIVE BIOSCIENCES, INC.
To: PHYSICIANS CHOICE LABORATORY SERVICES, LLC
Reel/Frame 032705/0646 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Dec 1, 2011
From: SHUBER, ANTHONY
To: PREDICTIVE BIOSCIENCES CORPORATION
Reel/Frame 027306/0888 →
Continuity (3)
Continuation In Part 12034698 · Feb 21, 2008
Provisional Application 60972507 · Sep 14, 2007
Related Publication 20120064529A1 · Mar 15, 2012